How many Europeans are affected by VKC?

Article

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

Dominique Brémond-Gignac of the Service d’Ophtalmologie, APHP, Hôpital Robert Debré, Paris, France and colleagues sent a survey to 3003 ophthalmologists across six countries with, cumulatively, 151.9 million inhabitants. The team analyzed the results to extrapolate data for number of VKC cases across the 15 European Union member states (2002). The survey response rate was 29.5% (n=886).

The team estimated 1.16–10.55 inhabitants per 10000 in Western European to be affected by VKC, with 0.30–2.26 per 10000 to be affected by VKC with corneal complications. The prevalence of VKC was found to be lower than expected in most countries questioned, although in Italy the range was 2.4–27.8/10000. However, the ranges for VKC prevalence were 0.7–8.4, 1.2–8.7, 0.6–4.6, 0.7–3.3 and 0.3–1.9 in Finland, Sweden, the Netherlands, France and Norway, respectively. The rate of VKC with corneal complications was 0.4–4.8, 0.3–2.4, 0.2–2.8, 0.2–1.6, 0.3–1.4 and 0.1–1.0 for each of these countries, respectively.

The team concluded that, based on the correlated and extrapolated data, it was most likely that VKC affects 3.2 of every 10000 people in Western Europe, and that the rate of corneal complications with the disease is 0.8 per 10000.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.